Etiology And Clinical Manifestations Of Type 3 Diabetes (Alzheimer's Disease)

The article explores the idea of "Type 3 diabetes," a phrase that is used to characterise Alzheimer's disease (AD) since it is linked to brain metabolic dysfunction and insulin resistance. Type 2 diabetes (T2D) and Alzheimer's disease (AD) are neurodegenerative disorders that are characterised by cognitive decline and memory impairment. Both disorders have many clinical markers, such as altered insulin signalling and glucose metabolism. This review looks at how insulin affects cognitive performance, how it affects brain function, and how insulin resistance and AD are related. In addition to being essential for controlling peripheral glucose, insulin also plays a crucial role in brain function, affecting synaptic plasticity, learning, and memory. The illness's two main hallmarks, the buildup of amyloid-beta (Aβ) peptides and the hyperphosphorylation of tau protein, are caused by impaired insulin signalling in the brain, or brain insulin resistance, in Alzheimer's disease. These mechanisms play a role in the development of amyloid plaques and neurofibrillary tangles, which are linked to neuronal death and cognitive impairment. There are several routes involved in the pathophysiology of AD. The disease associated with amyloid-β is caused by the amyloidogenic cleavage of the amyloid precursor protein (APP), which produces Aβ42 peptides that congregate and create plaques. Intracellular build-up of amyloid beta can upset the balance of cells, resulting in oxidative damage, malfunctioning mitochondria, and inflammation of the nervous system. Meanwhile, tau protein, which is responsible for maintaining the stability of neuronal microtubules, is hyperphosphorylated, misfolds, and clumps together to form neurofibrillary tangles, which worsens neuronal function and encourages cell death. Since AD and T2D share similar pathophysiological pathways, many treatment approaches are being investigated to address AD's brain insulin resistance. Metformin and thiazolidinediones (TZDs), two insulin-sensitizing medications, are being studied for their possible neuroprotective benefits through enhanced insulin signalling and decreased brain inflammation. Another cutting-edge strategy is intranasal insulin administration, which increases insulin availability in the brain and enhances cognitive performance by avoiding the blood-brain barrier. Furthermore, the dual roles that antidiabetic drugs like GLP-1 receptor agonists (such as exenatide and liraglutide) play in glucose control and neuroprotection are being investigated. The study also emphasises the need for medicines that address neuroinflammation and oxidative stress since they contribute to the development of AD. By regulating neurotransmitter activity and guarding against excitotoxicity, neuroprotective and cognitive enhancers such cholinesterase inhibitors and NMDA receptor antagonists provide symptomatic relief and decrease cognitive decline. Other approaches concentrate on encouraging neurogenesis to improve cognitive function and addressing the underlying metabolic dysfunctions. In conclusion, this review emphasises the significance of insulin and metabolic disorders in the aetiology of Alzheimer's disease, emphasising the potential benefits of treatments targeted at lowering neuroinflammation and restoring insulin sensitivity. By focussing on the metabolic foundations of Alzheimer's disease, new medicines that successfully manage or even stop the illness's progression may be developed as research into these pathways deepens.